Madison Square Garden filed paperwork on Friday with the SEC to separate its live sports and entertainment businesses from its media businesses.» Read More
Family Dollar adopted a one-year poison pill with a trigger of 10 percent, two days after Carl Icahn reported a stake in the company.
Drug giant Merck said it would purchase Idenix Pharmaceuticals for $3.85 billion, a deal already approved by both companies' board of directors.
Some of the names on the move ahead of the open.
Hillshire Brands is expected to declare Tyson the victor of a bidding war over itself, people briefed on the matter said on Sunday.
Kevin Smithen, Macquarie Securities, shares his thoughts on the pending mega-merger between Sprint and T-Mobile and what it might mean for the telecom industry.
CNBC's David Faber reports AT&T says it is confident regulators will approve the merger with DirecTV. Faber provides insight to the scale of the potential deal, and the impact to AT&T's content costs.
Stifel Financial said it would buy asset manager Legg Mason's investment advisory unit to expand its wealth management business.
Japan's Dai-ichi Life Insurance Co. has agreed to buy U.S. peer Protective Life for $5.7 billion, the largest acquisition by a Japanese insurer.
Pilgrim's Pride is planning to raise its offer for Hillshire a week after it first offered to buy it in a $6.4 billion deal.
Bob O'Donnell, Founder and Chief Analyst at Technalysis Research, outlines what Apple stands to benefit from its purchase of Beats Electronics.
CNBC's Sri Jegarajah breaks down the Apple-Beats deal in a unique rap.
Alex Gauna, MD & Senior Research Analyst at JMP Securities, outlines the doubts he has about Apple's acquisition of Beats Electronics.
Daniel Wiener, CEO, Adviser Investments, describes how the acquisition of Beats Electronics may give Apple a boost in the music-streaming space.
Pilgrim's Pride is offering to acquire meat producer Hillshire Brands in a deal worth about $5.52 billion.
Emilia Falcetti, Analyst, Japan Healthcare Equity Research at Cantor Fitzgerald, discusses whether Asian pharmaceuticals will follow their global peers in "ditching the diversification model."
The "Squawk on the Street" crew weigh in on the potential merger between tobacco companies Reynolds American and Lorillard.
Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.
CNBC's Meg Tirrell reports both Pfizer and AstraZeneca CEOs are facing tough questions by the UK Parliament on the possible merger.
Valeant said it planned to "improve" its $47 billion takeover offer for drugmaker Allergan, a day after the U.S. company rejected the bid.
U.S. medical firm Allergan rejected the unsolicited takeover offer from Valeant Pharmaceuticals, saying it substantially undervalued the company.